Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study
This first international real-world series of SG in mMpTNBC shows clinically relevant activity and manageable toxicity, addressing a critical evidence gap and supporting further prospective studies, particularly in PD-L1-positive disease.
Authors
- Renata Pacholczak‐Madej (ORCID: https://orcid.org/0000-0002-6535-4841)
- Maja Lisik-Habib
- Iwona Danielewicz (ORCID: https://orcid.org/0000-0002-5987-6272)
- Zuzana Bielčiková (ORCID: https://orcid.org/0000-0001-8434-9848)
- Miroslava Malejčíková
- Justyna Żubrowska (ORCID: https://orcid.org/0000-0002-7876-2537)
- Miloš Holánek (ORCID: https://orcid.org/0000-0003-1226-1593)
- Małgorzata Pieniążek (ORCID: https://orcid.org/0000-0001-5864-0877)
- Aleksandra Łacko
- Marcin Kubeczko (ORCID: https://orcid.org/0000-0003-1877-5691)
- Renata Soumarová
- Anna Polakiewicz-Gilowska (ORCID: https://orcid.org/0000-0002-2175-7067)
- Mirosława Püsküllüoğlu (ORCID: https://orcid.org/0000-0002-2647-9625)
- Aleksandra Konieczna (ORCID: https://orcid.org/0000-0001-8153-7923)
Institutions
- Jagiellonian University (PL)
- Charles University (CZ)
- Breast Cancer Care (GB)
- Copernicus Memorial Hospital (PL)
- Masaryk Memorial Cancer Institute (CZ)
- National Institute of Oncology (HU)
- Holy Cross University (PL)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- University Hospital Kralovske Vinohrady (CZ)
- National Cancer Research Institute (GB)
- Pomeranian Medical University (PL)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s10549-025-07875-4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00